What is it about?

The serum vascular adhesion protein-1 (VAP-1) level increases in chronic inflammatory diseases. The present study aimed to examine serum VAP-1 level in patients with stable chronic obstructive pulmonary disease (COPD) and the correlation of this marker with airflow limitation and health-related quality of life using the COPD Assessment Test (CAT).

Featured Image

Why is it important?

The study showed that serum VAP-1 level increased with an increasing severity of obstruction in patients with stable COPD. This increase was associated with a reduced quality of life and increased severity of hypoxia. These results suggest that inhibiting serum VAP-1 level in COPD patients may be useful in managing the disease.

Read the Original

This page is a summary of: Correlation of serum vascular adhesion protein-1 with airflow limitation and quality of life in stable chronic obstructive pulmonary disease, Respiratory Medicine, November 2017, Elsevier,
DOI: 10.1016/j.rmed.2017.10.011.
You can read the full text:

Read

Contributors

The following have contributed to this page